Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Novel compound, pharmaceutically acceptable salt or optical isomer thereof, method for preparing same, and pharmaceutical composition for prevention or treatment of viral diseases containing same as active ingredient

A technology of optical isomers, compounds, applied to novel compounds, pharmaceutically acceptable salts or optical isomers thereof, drugs for the preparation of them and drugs for preventing or treating viral diseases containing them as active ingredients In the field of composition, it can solve problems such as side effects, low treatment success rate, and unapproved antiviral drugs, and achieve low cytotoxicity

Active Publication Date: 2015-12-02
KOREA RES INST OF CHEM TECH +1
View PDF4 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the proven efficacy is not enough to make praconnelli registered in the United States (Picovir, Viropharma, USA) as a preparation for the treatment of rhinovirus infection
In March 2002, the corresponding application was rejected by the Food and Drug Administration (FDA) because of its low treatment success rate and observed side effects
[0012] However, antiviral drugs that have been developed for the treatment of enteroviruses or rhinoviruses have not yet been approved

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel compound, pharmaceutically acceptable salt or optical isomer thereof, method for preparing same, and pharmaceutical composition for prevention or treatment of viral diseases containing same as active ingredient
  • Novel compound, pharmaceutically acceptable salt or optical isomer thereof, method for preparing same, and pharmaceutical composition for prevention or treatment of viral diseases containing same as active ingredient
  • Novel compound, pharmaceutically acceptable salt or optical isomer thereof, method for preparing same, and pharmaceutical composition for prevention or treatment of viral diseases containing same as active ingredient

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0190] N-(4b-hydroxy-7-isopropyl-10-oxo-9b, 10-dihydro-4bH-benzo[d]indeno[1,2-b]furan-9b- Preparation of -2-(1H-indol-3-yl)-2-oxoacetamide

[0191] 2-(1H-indol-3-yl)-2-oxoacetic acid (352mg, 1.86mmol), EDCI (1-ethyl-3-(3-dimethylaminopropyl)carbodiimide) (355mg, 1.86mmol) and HOBt (hydroxybenzotriazole) (251mg, 1.86mmol) were dissolved in dichloromethane (MC) (10ml), then added 9b-amino-4b-hydroxy-7-isopropyl- 4bH-Benzo[d]indeno[1,2-b]furan-10(9bH)-one (500 mg, 1.69 mmol) and the mixture was stirred at room temperature for one day. The reaction mixture was extracted with dichloromethane to collect the organic layer, which was dissolved in MgSO 4 Dry under low temperature and concentrate under reduced pressure. The concentrated compound was purified by silica gel column chromatography (ethyl acetate:n-hexane=1:1) to obtain N-(4b-hydroxy-7-isopropyl-10-oxo-9b,10-dihydro-4bH-benzo [d] Indeno[1,2-b]furan-9b-yl)-2-(1H-indol-3-yl)-2-oxoacetamide (199 mg, 25%).

[0192] 1 H-NM...

Embodiment 2

[0194] N-(4b-hydroxy-7-isopropyl-10-oxo-9b, 10-dihydro-4bH-indeno[1,2-b]benzofuran-9b-yl)- Preparation of 2-oxo-2-(thiophen-2-yl)acetamide

[0195] After dissolving 2-oxo-2-(thiophen-2-yl)acetic acid (107mg, 1.07mmol) in DMF (3ml), the temperature was lowered to 0°C, and the solution was stirred. After 10 minutes, triethylamine (TEA) (213mg, 1.07mmol) and HATU (407mg, 1.07mmol) were added, stirred for 10 minutes before the temperature dropped to 0°C, and 9b-amino-4b-hydroxy-7-isopropyl yl-4bH-indeno[1,2-b]benzofuran-10(9bH)-one (300 mg, 1.02 mmol). Then, the temperature was raised to normal temperature, and the solution was stirred overnight. After washing with water, Na 2 SO 4 Remove moisture. After filtration and concentration, it was purified by column chromatography (EA:Hex=3:7) to obtain the title compound (52mg, 28%).

[0196] 1 H-NMR (300MHz, DMS0-d6) δ1.12 (d, 6H, J = 6.0Hz), 4.13 (q, 1H, J = 6.0Hz), 4.72 (s, 1H), 6.88 (d, 1H, J =6.0Hz),7.32(d,2H,J=6.0Hz),7.63...

Embodiment 3

[0198] N-(4b-hydroxyl-7-isopropyl-10-oxo-9b, 10-dihydro-4bH-indeno[1,2-b]benzofuran-9b-yl)- Preparation of 3-(2-nitrophenyl)-2-oxopropionamide

[0199] 2-Nitrophenylpyruvate (390mg, 1.86mmol) was placed in DMF:DCM (1:2, 15ml), and EDCI (487mg, 2.54mmol) was added at 0°C. Then, after adding 1-hydroxybenzotriazole (343 mg, 2.54 mmol), the mixture was stirred at room temperature for 15-30 minutes. Then, after adding 9b-amino-4b-hydroxyl-7-isopropyl-4bH-indeno[1,2-b]benzofuran-10(9bH)-one (500mg, 1.69mmol), TEA was added ( 0.709ml, 5.09mmol). After stirring at 60°C for 2 days, water (100ml) was added. The separated organic layer was collected and ethyl acetate (70mlx3), washed with water (50ml) and brine (50ml), and the water was removed with sodium sulfate. After concentration, it was purified by silica gel column chromatography (25% ethyl acetate: hexane) to obtain 100 mg (24%) of the title compound.

[0200] 1 H-NMR (300MHz, CDC1 3 )δ1.18(dd, J=2.7Hz, J=6.9Hz, 6H, CH3),...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to a novel compound, to a pharmaceutically acceptable salt or optical isomer thereof, to a method for preparing same, and to a pharmaceutical composition for the prevention or treatment of viral diseases containing same as an active ingredient. The novel compound according to the present invention not only has low cytotoxicity but also has excellent antiviral activity against picornavirus such as coxsackievirus, enterovirus, echovirus, poliovirus and rhinovirus, and thus can be effectively used as a pharmaceutical composition for the prevention or treatment of viral diseases such as infantile paralysis, acute hemorrhagic conjunctivitis, viral meningitis, hand-foot-and-mouth disease, vesicular disease, hepatitis A, myitis, myocarditis, pancreatitis, diabetes, epidemic myalgia, encephalitis, cold, herpangina, foot-and-mouth disease, asthma, chronic obstructive pulmonary disease, pneumonia, sinus infection, or otitis media.

Description

technical field [0001] The present invention relates to novel compounds, pharmaceutically acceptable salts or optical isomers thereof, methods for preparing them, and pharmaceutical compositions for preventing or treating viral diseases comprising them as active ingredients. Background technique [0002] Picornaviruses are non-enveloped positive single-stranded RNA viruses with RNA genomes 7.2-8.5 Kb in length. These viruses are very small, spherical, about 22-30nm in size, and were first identified a long time ago. Viruses belonging to the picornaviridae family are the genus Enterovirus and include rhinovirus, poliovirus, coxsackievirus A, coxsackievirus B, echovirus, and hepatitis A virus. [0003] Diseases caused by picornaviruses and RNA viruses range from respiratory to digestive, circulatory, to skin, examples include poliomyelitis, acute hemorrhagic conjunctivitis, viral meninges Inflammation, hand, foot and mouth disease, blistering disease, hepatitis A, myositis, ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07D405/12C07D409/12A61K31/4025A61P31/12
CPCC07D307/93C07D405/12C07D407/12C07D409/12C07D413/12C07D417/12A61P1/02A61P1/16A61P1/18A61P11/00A61P11/02A61P11/06A61P17/00A61P21/00A61P25/00A61P27/02A61P27/16A61P31/12A61P31/14A61P31/16A61P9/00A61P3/10Y02A50/30A61K31/404C07D307/79
Inventor 郑永植韩水逢李钟娇金海洙申珍洙约翰·奈茨亨德里克·杨·蒂博马尔帕尼·亚什沃德汉·拉德哈莫汉
Owner KOREA RES INST OF CHEM TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com